Protalix BioTherapeutics Set to Share Q1 2025 Insights Soon

Author: Owen Jenkins Updated: 05-05-2025 06:54 AM

Protalix BioTherapeutics to Report First Quarter Financials

Protalix BioTherapeutics, Inc. (NYSE American: PLX) is poised to announce its financial results for the first quarter of 2025, including insights into its business operations and clinical advancements. This information will be presented on May 9, 2025, during a dedicated conference call and webcast.

Conference Call to Discuss Results

Management is eager to engage with stakeholders and will lead a conference call to delve into the financial results. Participants can expect updates on key corporate initiatives and recent regulatory movements that are shaping the future of the company.

Details of the Conference Call

The conference call is scheduled for May 9, 2025, at 8:30 a.m. Eastern Daylight Time (EDT). Interested individuals can join using the following numbers:

Toll Free: 1-877-423-9813
International: 1-201-689-8573
Israeli Toll Free: 1-809-406-247

Additionally, the conference ID is 13753682, which participants will need to access the call efficiently.

Webcast Participation

Those unable to join the call can still participate through the webcast. Details to access the webcast include:

Company Link: Visit the investor relations section on the Protalix website for updates.
Webcast Link: Participants can join by accessing the specified webcast link.

As a reminder, it’s advisable for attendees to log in at least 15 minutes before the start time to ensure a smooth experience.

About Protalix BioTherapeutics, Inc.

Protalix is a pioneering biopharmaceutical company that specializes in developing and commercializing recombinant therapeutic proteins utilizing its innovative ProCellEx plant cell-based protein expression system. As a trailblazer in the industry, Protalix was the first to secure U.S. Food and Drug Administration (FDA) approval for a product produced through this unique plant cell method.

The company has established noteworthy partnerships, including its collaboration with Pfizer Inc., granting them the worldwide rights to taliglucerase alfa, which treats Gaucher disease. Protalix maintains manufacturing rights in select regions and continues to expand its portfolio.

Elfabrio, Protalix's second notable product, received FDA and European Medicines Agency approval, further cementing its reputation for developing effective therapeutic solutions.

In addition to successful product launches, Protalix boasts a robust development pipeline with several candidates targeting significant medical needs. This includes PRX–115, intended for treating uncontrolled gout, and PRX–119, aimed at addressing diseases related to NETs.

Investor Contact Information

For investor inquiries, reach out to Mike Moyer, Managing Director at LifeSci Advisors. He is available at +1-617-308-4306 for discussions involving investment opportunities or financial details.

Frequently Asked Questions

When will Protalix report its Q1 2025 financial results?

Protalix is scheduled to report these results on May 9, 2025.

How can I participate in the conference call?

Participants can join the call by dialing the toll-free or international numbers provided, using the conference ID 13753682.

What products has Protalix developed?

Protalix has developed products such as taliglucerase alfa for Gaucher disease and Elfabrio, which have received regulatory approval.

How can I access the webcast?

The webcast can be accessed by visiting Protalix's investor relations section on their website or through the direct webcast link on the day of the event.

Who can I contact for investor relations?

Mike Moyer, Managing Director at LifeSci Advisors, is the contact for investor relations and can be reached at +1-617-308-4306.

About The Author

Hi there I'm 38-year-old author and financial consultant Owen Jenkins. Having worked in the financial sector for more than ten years, I am well-versed in the subtleties and complexity that mold our financial environment. Following a degree in finance, I worked in a number of financial institutions honing my abilities in market analysis, financial planning, and investment strategies.

My love is teaching others about investing and personal finance. My goal in writing many books and articles has been to demystify financial ideas and give readers the information they need to make wise financial decisions. I write with a direct, useful style that emphasizes doable suggestions for daily living.

Along with writing, I lead webinars and seminars where I impart knowledge on how to successfully negotiate the financial world. I also write for financial journals and show up as a guest expert on financial news programs a lot. Whether they are new to investing or want to improve their approach, my mission is to enable people to take charge of their financial futures.

Beyond work, I like to hike, play the guitar, and spend time with my family. I think that balance is crucial and want to encourage people to strike a balance between their financial aspirations and their hobbies. I want to help people succeed and achieve financial security through my work, so having a good influence.

Contact Owen Jenkins privately here. Or send an email with ATTN: Owen Jenkins as the subject to contact@investorshangout.com.

About Investors Hangout

Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/

The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.